
10 Posts Not to Miss from EHA 2025
The European Hematology Association (EHA) Congress 2025 is officially underway in Milan. From June 12 to 15, hematology professionals from around the world are gathering to share the latest research, clinical advances, and innovations shaping the future of hematologic care.
EHA 2025 features a comprehensive scientific program that includes high-level plenary sessions, oral abstract presentations, clinical and translational research highlights, and disease-specific updates across malignant and non-malignant hematologic conditions. With hundreds of abstracts presented, as well as interactive education sessions and collaborative forums, the congress offers unparalleled insight into evolving standards of care, novel therapies, and mechanisms of disease.
This year’s meeting also celebrates the 30th edition of the EHA Congress, a milestone reflecting three decades of scientific excellence, global collaboration, and commitment to improving outcomes for patients with blood disorders. The program places a strong emphasis on innovation, equity, and mentorship, highlighted by prestigious award recognitions honoring leaders in the field.
Our team at OncoDaily has handpicked 10 highlights from the firts day of EHA 2025. Scroll down to catch the highlights, dive into the science, and hear directly from the people shaping the future of cancer care.


at EHA 2025 in between sessions !”



“Very productive first meeting with my mentee Thanks European Hematology Association for this mentorship program.”





To stay on top of everything happening at EHA 2025, keep following Hemostasis Today.
Written by Nare Hovhannisyan, MD
-
Sep 14, 2025, 11:17Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
-
Sep 13, 2025, 13:32Beta Thalassemia Major After Splenectomy: Setareh Sheikhi Reports Striking nRBC Surge Reports Striking nRBC Surge
-
Sep 13, 2025, 13:26Global Blood and Plasma Collections and Use 2023–2024: Trends, Regulations, and Market Insights
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 14, 2025, 14:36Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
-
Sep 14, 2025, 12:37Ivan Budnik Highlights New Framework for Thrombus Resolution Analysis in Mouse IVC Stenosis Model
-
Sep 14, 2025, 04:16F8 Gene Variants Affect Desmopressin Response in Female Hemophilia A Carriers
-
Sep 13, 2025, 13:35Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
-
Sep 13, 2025, 13:20Giulia Simini: Our Review on the Hepatic Life Cycle of AAV is Now Available in JTH
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 14, 2025, 06:39Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 13, 2025, 06:49Emna Gouider Belhadjali on the Role of NMOs in Advocating for Equitable Access to Diagnosis for WGBDs
-
Sep 12, 2025, 09:30Arun V J Explains How Blood Donation Rules Differ Worldwide and Why Your Donation Saves Lives Everywhere